The effect of switching patients from risedronate to alendronate on the risk of upper gastrointestinal (GI) adverse events after the introduction of generic alendronate products in the UK

S. H. Ralston, T. D. Kuo, B. Wick-Urban, M. Steinbuch

Research output: Contribution to journalMeeting abstractpeer-review

Original languageEnglish
Pages (from-to)S446-S446
Number of pages1
Issue number2
Publication statusPublished - Jun 2009

Cite this